Actively Recruiting
A Clinico-biological Database of Lung Cancers
Led by University Hospital, Lille · Updated on 2026-05-22
500
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
U
University Hospital, Lille
Lead Sponsor
I
Institut Pasteur de Lille
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are establishing a clinico-biological database for lung cancer by collecting biological samples and clinical data from patients. This observational study focuses on identifying biological, clinical, and tumor factors linked to tumor response to standard of care treatments. The study includes patients newly diagnosed with lung cancer or suspected lung tumors where antineoplastic treatment is planned. Participants provide blood samples, optional tumor tissue biopsies, and fecal samples at several points: before treatment starts, at the first tumor assessment, and at the first and second disease progressions. Genetic analysis is conducted on tumor or healthy tissue and blood to assess constitutional and somatic alterations. All treatments are given as part of standard care without experimental interventions. Throughout the study, clinical data are collected concurrently with sample collection to monitor disease progression and treatment response. The main outcome measured is the tumor response rate evaluated by CT scan after 8 weeks. Secondary outcomes include disease progression rate, progression-free survival, overall survival over one year, and treatment toxicity. Participants are followed over time with repeated assessments and sample collections to support the research objectives.
CONDITIONS
Brief Title
A Clinico-biological Database of Lung Cancers
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Documented new diagnosis of lung cancer by histology or cytology, or lung tumor suspected of lung cancer for which antineoplastic treatment is planned
- Indication for first line lung cancer treatment by surgery, chemotherapy, radio-chemotherapy, radiotherapy, or targeted therapy
- Ability to follow study procedures
- Age 18 years or older
- At least one measurable or assessable lesion by RECIST 1.1 criteria
- Registered with a social security scheme
- Receiving care at Pneumology department of Lille University Hospital
- Signed informed consent form
You will not qualify if you...
- History of antineoplastic chemotherapy, radio-chemotherapy, radiotherapy, or targeted therapy, or contraindication to antineoplastic treatment
- Unwilling to sign the informed consent form
- Not registered with a social security scheme
- Not francophone
- Deprived of liberty or under trusteeship
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 8 weeks
Participants undergo diagnostic procedures including tissue biopsies and blood sampling to collect tumor and healthy tissue samples as well as blood for genetic analysis.
Visits occur during standard diagnostic or therapeutic procedures
Duration - Up to 1 year
Participants are monitored over time to assess tumor response, disease progression, survival, and treatment toxicity as part of routine care.
Follow-up visits coordinated with routine clinical care up to 1 year
Trial Site Locations
Total: 1 location
1
Hôpital Calmette, CHU
Lille, France
Actively Recruiting
Research Team
A
Alexis CORTOT, MD,PhD
E
Eric WASIELEWSKI, M
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here